Loading...
•
Jun 30, 2020
Verastem Q2 2020 Earnings Report
Verastem Oncology announced the sale of COPIKTRA® rights to Secura Bio and a focus on development of VS-6766 and Defactinib.
Key Takeaways
Verastem Oncology entered into a definitive agreement to sell its global commercial and development rights to COPIKTRA to Secura Bio for $70 million up-front, with a total deal value up to $311 million plus royalties. Verastem will focus on developing VS-6766 and Defactinib in KRAS mutant solid tumors, with current programs funded until at least 2024.
Verastem will receive $70 million up-front with a total deal value up to $311 million from Secura Bio.
Verastem will focus on the development of VS-6766 and Defactinib in KRAS mutant solid tumors.
Phase 2 registration-directed trials are expected to commence by year end 2020 in low-grade serous ovarian cancer and KRAS mutant non-small cell lung cancer.
Enrollment in the ongoing investigator-initiated Phase 1/2 FRAME study of VS-6766 and Defactinib is expanding to include pancreatic, KRAS mutant endometrial and KRAS-G12V non-small cell lung cancer cohorts.
Forward Guidance
Verastem Oncology provides forward-looking statements about its strategy, future plans, and prospects, including the expected sale of COPIKTRA and the potential clinical value of RAF/MEK/FAK combination.
Positive Outlook
- The transaction with Secura Bio is expected to close in the third quarter of 2020.
- The FDA was supportive of the Company’s development strategy and adaptive design for LGSOC.
- Verastem expects to commence registration-directed clinical trials for potential accelerated approval in LGSOC and KRASmt NSCLC by the end of 2020.
- The FRAME study is expanding in August 2020 to include new cohorts in pancreatic, KRASmt endometrial and KRAS-G12V NSCLC.
- With the sale of COPIKTRA, Verastem will become a focused development company with reduced annual expenses of approximately $50 million and is in a position of financial strength with a cash runway expected to fund the clinical and regulatory milestones and development of VS-6766 and defactinib in LGSOC and KRASmt NSCLC until at least 2024.
Challenges Ahead
- The satisfaction of closing conditions with respect to the sale of the COPIKTRA assets to Secura Bio.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...